December 2019 Vol 5 No 6

In November 2019, the FDA approved the second Bruton tyrosine kinase inhibitor for the treatment of adults with mantle-cell lymphoma (a type of non-Hodgkin lymphoma) who have received at least 1 previous therapy. Read More ›

In November 2019, the FDA approved a new treatment, Calquence, for patients with relapsed or refractory CLL or SLL. Read More ›

Late last year, the PARP inhibitor Zejula was approved by the FDA for patients with HRD mutation associated with advanced ovarian, fallopian tube, or primary peritoneal cancer, offering a new treatment option for women with these types of cancer. Read More ›

Late in 2019, the FDA approved the combination of immunotherapy plus chemotherapy as the first-line treatment for patients with non–small-cell lung cancer that does not harbor EGFR or ALK mutations, which are often associated with lung cancer. Read More ›

Myelodysplastic syndromes are a group of cancers that affect immature blood cells in the bone marrow. Two oncology navigators explain the risk factors and current treatment options available for patients diagnosed with this type of malignancy. Read More ›

People who are diagnosed with blood cancer need to learn enough about it without being overwhelmed, and to take part in their treatment decisions. Communicate important personal information to your care team. Read More ›